Basic research of mechanism of malignant pheochromocytoma
Project/Area Number |
23591889
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | University of Tsukuba |
Principal Investigator |
HARA Hisato 筑波大学, 医学医療系, 教授 (80189688)
|
Co-Investigator(Kenkyū-buntansha) |
TAKEKOSHI Kazuhiro 筑波大学, 医学医療系, 教授 (40261804)
ISHII Kiyoaki 筑波大学, 医学医療系, 助教 (80419150)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
Keywords | 褐色細胞腫 / mTOR / mTOR |
Research Abstract |
This research was performed to explore the malignant potential of phechromocytoma and the mechanism of effect of molecular targetted therapy. We examined that Rat pheochromocytoma cell line PC12 was treated with mTOR inhibitor and Sunitinib. Antiproliferative effect and the increase of apoptosis effect was showed. We demonstrated that sunitinib significantly increased the levels of LC3-II.Following sunitinib treatment, immunofluorescent imaging revealed a marked increased punctate LC3-II distribution.Inhibition of autophagy by siRNAs targeting Atg13 or by pharmacological inhibition with ammonium chloride, enhanced both sunitinib-induced apoptosis and anti-proliferation. Inhibition of autophagy may be a promising therapeutic option for improving the anti-tumor effect of sunitinib.
|
Report
(4 results)
Research Products
(10 results)